NASDAQ:CLRB - Cellectar Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.80 -0.58 (-7.86 %)
(As of 07/18/2018 04:00 PM ET)
Previous Close$7.38
Today's Range$6.35 - $12.00
52-Week Range$5.70 - $20.60
Volume664,000 shs
Average Volume60,951 shs
Market Capitalization$13.26 million
P/E Ratio-6.36
Dividend YieldN/A
Cellectar Biosciences logoCellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) therapeutic, CLR 131, is in a Phase 1 clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a range of B-cell malignancies. The company's product pipeline also includes two preclinical PDC chemotherapeutic programs, which include CLR 1700 that is designed to treat a broad range of hematologic cancers; and CLR 1900, which is targeted to treat select solid tumors. It also has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; with Avicenna Oncology GMBH to develop CLR 2000 Series; and Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio3.64
Quick Ratio3.64


Trailing P/E Ratio-6.36
Forward P/E Ratio-9.32
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.62 per share
Price / Book10.97


EPS (Most Recent Fiscal Year)($1.07)
Net Income$-13,560,000.00
Net MarginsN/A
Return on Equity-178.37%
Return on Assets-139.16%


Outstanding Shares17,710,000
Market Cap$13.26

The Truth About Cryptocurrencies

Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work?

Shares of Cellectar Biosciences reverse split on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences Inc (NASDAQ:CLRB) posted its quarterly earnings results on Friday, May, 11th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the Zacks' consensus estimate of ($2.00) by $0.10. View Cellectar Biosciences' Earnings History.

When is Cellectar Biosciences' next earnings date?

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Cellectar Biosciences.

What is the consensus analysts' recommendation for Cellectar Biosciences?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Cellectar Biosciences' key competitors?

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the folowing people:
  • Mr. James V. Caruso, CEO, Pres & Director (Age 59)
  • Mr. Jarrod Longcor, Chief Bus. Officer (Age 45)
  • Dr. John E Friend II, M.D., VP & Chief Medical Officer (Age 48)
  • Mr. Brian M. Posner, VP & CFO (Age 56)
  • Gregory J. Lynch, Sec.

Has Cellectar Biosciences been receiving favorable news coverage?

Press coverage about CLRB stock has trended somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectar Biosciences earned a news impact score of 0.03 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $6.80.

How big of a company is Cellectar Biosciences?

Cellectar Biosciences has a market capitalization of $13.26 million. The biopharmaceutical company earns $-13,560,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Cellectar Biosciences employs 15 workers across the globe.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 3301 AGRICULTURE DRIVE, MADISON WI, 53716. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]

MarketBeat Community Rating for Cellectar Biosciences (NASDAQ CLRB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  187
MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe CLRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.